Pathway enrichments in HSC/MPPs and CMP/MEPs of patients with PV and controls on the protein and RNA level. (A) GSEA comparing untreated patients with PV against controls (PV.UT.HSC/MPP vs Control.HSC/MPP) and assessing for the effects of treatment with HU (PV.HU.HSC/MPP vs PV.UT.HSC/MPP) and differentiation (PV.UT.HSC/MPP vs PV.UT.CMP/MEP). Shown are normalized enrichment scores for perturbed gene sets, whereby FDR < 0.25 denotes significantly enriched gene sets (marked by intense colors).38 (B) Heatmap of core-enriched RNAs in HSC/MPPs of patient and control groups for the cell polarity pathway epithelial-mesenchymal transition. (C) Heatmap of core-enriched proteins in HSC/MPPs of patient and control groups for the cell polarity pathway epithelial-mesenchymal transition.